



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : H. Deuttmann) Art Unit: 1614
U.S. Appln. No. : 10/601,205) Examiner: To be assigned
Confirmation No. : 7346
U.S. Filing Date : June 20, 2003
Title of Invention : DRUG COMBINATIONS BASED ON MAGNESIUM SALTS AND
FIBRINOLYTICS
Attny. Docket No.: 1/1362

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

December 18, 2003

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

☒ 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

☐ A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).

☐ 1.97(e).

☐ Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or

☐ No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,



Mary-ellen M. Devlin
Attorney for Applicant(s)
Reg. No. 27,928


Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4866
Date:

Certificate of Mailing


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents
P. O. Box 1450
Alexandria, VA 22313-1450

on December 18, 2003.



Mary-ellen M. Devlin, Reg. No. 27,928



Complete if Known

Application Number	10/601,205
Filing Date	June 20, 2003
First Named Inventor	H. Duetmann
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	1/1362

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ⁵ (if known)				
		WO 9732585	09/12/1997	Medinox, Inc.		
		SU 1084024	04/07/1984	Leningrad Research Inst. of Vaccines and Sera		
		GB 872146	07/05/1961	I. Innerfield		

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/601,205
				Filing Date	June 20, 2003
				First Named Inventor	H. Duetmann
				Art Unit	1614
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	1/1362

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Database WPI, Section Ch, Week 198447, Derwent Publications Ltd., London, GB; Class B04, AN 1984-293724 XP002257350 & SU 1 084 024 A (Lengd Vaccine Sera), 04/07/1984	
		Hacke, W. et al: "Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)" <i>Lancet</i> , XX, XX, Volume 352, Number 9136, Oct. 17 1998, Pages 1245-1251, XP004265690, ISN: 0140-6736	
		Nagai, N. et al: "Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models" <i>Circulation</i> , Vol. 100, No. 25, Dec. 21, 1999, Pages 2541-2546, XP002258347, ISSN: 009-7322	
		Serrano, Ramon L. et al: "ATP-regulated activity of the plasmin-streptokinase complex: A novel mechanism involving phosphorylation of streptokinase" <i>Biochemical Journal</i> , Vol. 313, No. 1, 1996, Pages 171-17, XP002257347, ISSN: 0264-6021, Page 176	
		Foster, Thomas M. et al: "Thermal stability of low molecular weight urokinase during heat treatment: III. Effect of salts, sugars and tween 80: <i>International Journal of Pharmaceutics</i> (Amsterdam), Vol. 134, No. 1-2, 1996, pages 193-201 XP002257348, ISSN: 0378-5173, page 197, page 200	
		ROTE Liste Service GmbH: "Rote Liste 1997", 1997, ECV - Editio Cantor - Aulendorf/Wuertt, Frankfurt/Main XP002257349 - with translation	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.